NCT07678242

Brief Summary

The purpose of this clinical trial is to learn about the impact of the Healthy Minds Program (HMP) on measurements of well-being. The main question it aims to answer is:

  • Does use of HMP reduce symptoms of depression? Participants will complete a 4-week well-being program.

Trial Health

65
Monitor

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
1,500

participants targeted

Target at P75+ for not_applicable

Timeline
24mo left

Started Aug 2026

Typical duration for not_applicable

Status
not yet recruiting

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

June 24, 2026

Completed
7 days until next milestone

First Posted

Study publicly available on registry

July 1, 2026

Completed
1 month until next milestone

Study Start

First participant enrolled

August 1, 2026

Completed
2 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

August 1, 2028

Expected
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

August 1, 2028

Last Updated

July 1, 2026

Status Verified

June 1, 2026

Enrollment Period

2 years

First QC Date

June 24, 2026

Last Update Submit

June 24, 2026

Conditions

Outcome Measures

Primary Outcomes (1)

  • Change in Physical Health Questionnaire depression scale (PHQ-9)

    The PHQ-9 is a 9-question screening tool used to assess depression severity. Each of the 9 items evaluates symptoms over the last 2 weeks and is scored from 0 (not at all) to 3 (nearly every day), resulting in a total possible score ranging from 0 to 27. Higher scores indicate higher depression severity.

    Baseline, 1 week, 2 weeks, 3 weeks, 4 weeks, 3 months

Secondary Outcomes (8)

  • Change in Generalized Anxiety Disorder (GAD-7) score

    Baseline, 1 week, 2 weeks, 3 weeks, 4 weeks, 3 months

  • Change in Flourishing Measure

    Baseline, 1 week, 2 weeks, 3 weeks, 4 weeks, 3 months

  • Change in PROMIS Sleep Disturbance

    Baseline, 1 week, 2 weeks, 3 weeks, 4 weeks, 3 months

  • Change in performance on the behavioral Self-Referential Encoding Task (SRET)

    Baseline, 1 week, 2 weeks, 3 weeks, 4 weeks, 3 months

  • Change in self-referential thought

    Baseline, 1 week, 2 weeks, 3 weeks, 4 weeks, 3 months

  • +3 more secondary outcomes

Study Arms (3)

Healthy Minds Program (HMP)

EXPERIMENTAL

Participants will use HMP

Device: Healthy Minds Program

Active control group

ACTIVE COMPARATOR

Participants will play mental games

Behavioral: Healthy Minds Brian Games

Usual care group

ACTIVE COMPARATOR
Behavioral: Care as usual

Interventions

A mobile health meditation training program.

Healthy Minds Program (HMP)

Typescript-based games installed as a web application

Active control group
Care as usualBEHAVIORAL

Care as usual

Usual care group

Eligibility Criteria

Age18 Years - 84 Years
Sexall
Healthy VolunteersYes
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Age 18 to 84
  • Elevated depressive symptoms: PHQ-9 ≥ 10; Healthy controls: PHQ-9 \<5
  • Proficient in English to try to unsure understanding of study requirement, consent forms and questionnaires that can often us medical terms not routinely used in general conversation.
  • Able to provide informed consent
  • Have access to a smartphone that can download apps from Google Play or the Apple App Store
  • Ability to receive text messages
  • Indicate interest in participation after being informed of restrictions to payment

You may not qualify if:

  • Regular daily meditation practice for past 6 months or regular weekly meditation practice for past 12 months
  • Attended a meditation retreat or a yoga/body practice retreat with a significant meditation component
  • Previous use of Healthy Minds Program app
  • Current suicidal intent and/or high self-injury risk (determined by PHQ-9 item 9 and BDI item 9)
  • Self-reported history of psychosis
  • Self-reported history of mania
  • Hearing impairments
  • Prior participation
  • Self report pregnancy

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Officials

  • Jo Handelsman, PhD

    University of Wisconsin, Madison

    PRINCIPAL INVESTIGATOR

Central Study Contacts

Sarah Effertz

CONTACT

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
NONE
Purpose
TREATMENT
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

June 24, 2026

First Posted

July 1, 2026

Study Start

August 1, 2026

Primary Completion (Estimated)

August 1, 2028

Study Completion (Estimated)

August 1, 2028

Last Updated

July 1, 2026

Record last verified: 2026-06

Data Sharing

IPD Sharing
Will share

De-identified individual participant data will be shared.

Shared Documents
STUDY PROTOCOL, SAP
Time Frame
IPD will be available upon reasonable request after study completion.
Access Criteria
Requests will be reviewed by the study PI, and data will be shared under a data use agreement.